clinical trial · NCT07399132
A Study of APL-10456-Vaccine
RhinovirusAPL-10456-VaccinePlacebo
brief summary
AP09CP01 is a Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study which is conducted in Australia. The main purpose of this research study is to evaluate the safety, side effects, and immune response of APL-10456-Vaccine, a Rhinovirus (RV) Vaccine, when compared with a placebo in Younger and Older Healthy Volunteers
started
Feb 16, 2026
primary completion
Aug 2, 2026
completion
Oct 21, 2027
last updated
Feb 19, 2026
official title
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Two-Part Study to Evaluate the Safety, Tolerability, and Immunogenicity of APL-10456-Vaccine in Healthy Volunteers
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol